Access to CAR T-cell therapy: Focus on diversity, equity and inclusion

Access offsets poverty in quest for CAR T cells

(2023) Rayne H. Rouce et al.   BLOOD

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).

(2023) Adam Samuel Sperling et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical trial participation predicts improved survival in older adults receiving allogeneic blood and marrow transplant

(2023) Clifton P. Thornton et al.   BMC Geriatrics

Equitable access to cell and gene therapies in South Africa: opportunities and hurdles

(2022) Candice Laverne Hendricks et al.   GENE THERAPY

Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India

(2022) Kenneth Cornetta et al.   MOLECULAR THERAPY

Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma

(2022) Alice J. Chen et al.   VALUE IN HEALTH

Systematic Review of Available CAR-T Cell Trials around the World

(2022) Luciana Rodrigues Carvalho Barros et al.   Cancers

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms

(2022) Samer Al Hadidi et al.   JAMA Network Open

CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions

(2022) Claudio Jommi et al.   Frontiers in Pharmacology

The journey of CAR-T therapy in hematological malignancies

(2022) Junru Lu et al.   Molecular Cancer

Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper

(2022) Nico Gagelmann et al.   Lancet Haematology

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

(2022) Raghad Alqazaqi et al.   JAMA Network Open

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil

(2022) Vania Hungria et al.   Hematology Transfusion and Cell Therapy

Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy

(2022) Haley Newman et al.   BLOOD

Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India

(2022) Hamenth Kumar Palani et al.   BONE MARROW TRANSPLANTATION

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management

(2021) Sandra Susanibar‐Adaniya et al.   AMERICAN JOURNAL OF HEMATOLOGY

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma

(2021) Sophie Snyder et al.   ADVANCES IN THERAPY

CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes

(2021) Akshay Ravindranath et al.   CYTOTHERAPY

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

(2020) Karl M. Kilgore et al.   BLOOD

Value and affordability of CAR T-cell therapy in the United States

(2020) Salvatore Fiorenza et al.   BONE MARROW TRANSPLANTATION

Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma

(2020) Ajeet Gajra et al.   Immunotherapy

CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies

(2020) Blake J Rust et al.   Lancet Haematology

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

(2020) Jeremy S Abramson et al.   LANCET

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China

(2020) Zhitao Ying et al.   Cancer Medicine

An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer

(2019) Steven Feins et al.   AMERICAN JOURNAL OF HEMATOLOGY

CART manufacturing process and reasons for academy-pharma collaboration

(2019) Natalia Egri et al.   IMMUNOLOGY LETTERS

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

(2018) Inmaculada Hernandez et al.   JAMA Oncology

Increasing Diversity in Clinical Trials: Overcoming Critical Barriers

(2018) Luther T. Clark et al.   CURRENT PROBLEMS IN CARDIOLOGY

Inequality and the health-care system in the USA

(2017) Samuel L Dickman et al.   LANCET

The why, what, and how of the new FACT standards for immune effector cells

(2017) Marcela V. Maus et al.   Journal for ImmunoTherapy of Cancer

County Health Rankings

(2016) Carlyn M. Hood et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Structural Racism and Supporting Black Lives — The Role of Health Professionals

(2016) Rachel R. Hardeman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient Income Level and Cancer Clinical Trial Participation

(2013) Joseph M. Unger et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute lymphoblastic leukaemia in children with Down syndrome: an updated review

(2011) Kelly W. Maloney   BRITISH JOURNAL OF HAEMATOLOGY

Does a Higher Income Have Positive Health Effects? Using the Earned Income Tax Credit to Explore the Income-Health Gradient

(2011) JEFF LARRIMORE   MILBANK QUARTERLY